ESMO 2017 | Is lorlatinib a better option for NSCLC?

Benjamin Besse, MD, PhD, from the Gustave Roussy Cancer Institute, Paris, France, discusses recent study in the treatment of non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Lorlatinib is a potent third generation ALK and ROS1 inhibitor that is currently being developed. A study investigating lorlatinib in the treatment of ALK-positive or ROS1-positive NSCLC (NCT02927340) found a high response rate, with a large proportion of patients either disease free or progression free after a year, a very positive result.